Last reviewed · How we verify
BCD-131
BCD-131 is a small molecule that targets the [insert target here, if known].
At a glance
| Generic name | BCD-131 |
|---|---|
| Also known as | pegylated darbepoetin beta, pegylated darbepoetin alfa |
| Sponsor | Biocad |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, I do not have information on the specific mechanism of action of BCD-131.
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis (PHASE2)
- Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |